Monday, June 25, 2012

Impaled in a Rowing Accident

This article I dredged up from the archives is mostly of sentimental value - although, I could claim it's related to Olympic sport-related trauma with the upcoming Games.


This is from the series "Case records of the Massachusetts General Hospital", which run the gamut all the way out to some of the most esoteric diagnoses possible.  This particular article describes the management and outcomes of a man impaled by a rowing shell while on the Charles River.  Eight-person rowing shells are ~17 meters in length, have a crewed weight of nearly 1,000 kg, and travel fast enough that a water skier may be towed behind.  There is a small rubber bumper affixed to the, otherwise sharp, wooden or carbon-fiber bow that is meant to reduce the potential for injury in event of a collision.  In this incident, the momentum of a head-on impact dislodged the bow ball and resulted in the unfortunate impalement incident described.  A fascinating little read.


Rowing collisions are uncommon, injuries are rare, and this is probably nearly unique.


"Case records of the Massachusetts General Hospital. Case 10-2007. A 55-year-old manimpaled in a rowing accident."
www.ncbi.nlm.nih.gov/pubmed/17392306

Friday, June 22, 2012

Nephropathy Was As Common as PE after CTPA

It's Jeff Kline Week at EMLitOfNote, with the second Carolinas paper this week - and, as a Patient Safety and Quality Fellow, I just can't help but cite articles that deal with the consequences of otherwise well-meaning practice.

This small study followed 174 patients undergoing CTPA demonstrated a yield of 7% for PE.  On the other hand, this same cohort demonstrated a yield of 14% for contrast-induced nephropathy - as defined by an increase in serum Cr of 0.5 mg/dL or >25%.  Three of the 24 patients with CIN progressed to severe renal failure, two of whom died.  The proportion of CIN and renal failure were similar to the outcomes observed in the additional 459 patients they followed for CT imaging on other contrast protocols.

So, the rate of CIN is not insignificant - particularly compared to the rate of diagnosis of PE at this institution.  It seems to be suggested by this study, although not shown, that the relative risk of death conferred by receiving contrast and developing CIN might even exceed the number of adverse events that might have occurred from PE if left undiagnosed or untreated.

"Prospective Study of the Incidence of Contrast-induced Nephropathy Among Patients Evaluated for Pulmonary Embolism by Contrast-enhanced Computed Tomography"
http://www.ncbi.nlm.nih.gov/pubmed/22687176

Wednesday, June 20, 2012

Chest Pain - Here, Your Problem Now

In the United States, a quarter of our medical malpractice payments result from missed myocardial infarctions.  Therefore, in states with sub-optimal liability environments, emergency physicians are stuck in a quagmire of conflicted interests and fear of litigation if a discharged patient has an MI.

Therefore, a common strategy is to make low-risk chest pain Someone Else's Problem.  And, this article from Archives of Internal Medicine shows the internist evaluating the patient simply makes the same surrender to defensive medicine.  In this retrospective cohort, 2,107 admitted patients underwent 1,474 stress tests during their two-year study period.  Of those 1,474, 12.5% were abnormal.  Of those 184 patients, only 11.6% underwent cardiac catheterization, and a grand total of 9 patients received a revascularization.

So, the authors suggest two salient points:
 - 2,107 admissions to yield 9 (supposedly) beneficial interventions - how crazy is that?
 - What about the 88.4% of patients with abnormal stress tests that didn't undergo an invasive test within 30 days - why are we using an evaluation strategy we don't act on?

The authors think we might be able improve upon this practice pattern.

"Outcomes of Patients Admitted for Observation of Chest Pain"
www.ncbi.nlm.nih.gov/pubmed/22566486

Monday, June 18, 2012

National Quality Measure for Pulmonary Embolism

The overuse of CTA in the Emergency Department and the over-diagnosis of pulmonary emboli of non-physiologic significance has been demonstrated as a significant societal harm.  In response to this, the National Quality Forum has been looking at developing a quality measure aimed at reducing CTA use in the Emergency Department.

The NQF estimated 7 to 25% of CTAs in the ED might be unnecessary.  From Jeff Kline's shop at Carolinas, they prospectively gathered data on all their potential pulmonary emboli and attempted to determine which scans were "inappropriate."  For their purposes, a scan was "inappropriate" if it was a low-risk patient with a negative D-dimer assay, or it was a low-risk patient without D-dimer testing.  11% were D-dimer negative and 22% were low-risk without D-dimer testing performed, which sums to 32% potentially avoidable imaging.

Of the 1,205 "potentially avoidable" scans, there were 58 positives.  The clinical significance of these potential misses is uncertain.  Whether this represents an acceptable miss rate for a quality measure in a liability prone environment is another matter entirely.

"Evaluation of Pulmonary Embolism in the Emergency Department and Consistency With a National Quality Measure"
www.ncbi.nlm.nih.gov/pubmed/22664742

Friday, June 15, 2012

How to Be Popular at the Beach

The summer is a great time for swimming - and, luckily, there's an evidence-based systematic review of treatment of jellyfish stings available from Annals of Emergency Medicine.  Unfortunately, it's only the relatively benign and inconvenient species from North America, rather than the life-threatening species found more commonly in the southern hemisphere.

Literally, everything has been tried on jellyfish stings in an attempted in treatment, from vinegar, to ammonia, to ethanol, to meat tenderizer, to magnesium chloride, and the list goes on.  Essentially, the attempted treatments fall into two camps - wash off the nematocysts without inducing discharge, or simply to treat the pain and tissue damage from the venom itself.

The American Red Cross First Aid consensus suggests the use of vinegar - which, according to this review, induces nematocyst discharge in everything but some Physalia species.  The real answer is...no single agent reliably inactivates nematocysts from every organism.  The authors recommend simply using readily available saltwater to wash the affected area.  For post-envenomation pain, topical anesthetics such as lidocaine and hot water were found to be most reliably effective.  Given the limited availability of anesthetics to laypersons, the best treatment is likely to be hot water submersion to help inactivate the toxins.

"Evidence-Based Treatment of Jellyfish Stings in North America and Hawaii"
www.ncbi.nlm.nih.gov/pubmed/22677532

Wednesday, June 13, 2012

A Little Proof of Harms from CTs

It is popular to worry about the harms of CT scans in small children.  A retrospective Swedish study suggests decreased intelligence.  And, our models based on nuclear weapon exposure data combined with dummy CT exposure suggest these scans are likely to result in an increased risk of malignancy.

This is another retrospective study in the National Health Service of Britain comparing malignancy outcomes with their exposure to CT in childhood.  The scary headline: CT scan radiation triples the risk of leukemia and primary brain malignancy.  Of course, triple the risk is essentially 1 additional case of leukemia and 1 additional case of primary brain malignancy in the first 10 years after exposure.  So, this is potentially another study you can use to discuss the Number Needed to Harm with families when discussing the need for CT radiation in pediatric cases.

Now, whether articles like this trigger a wave of legal trolling for malignancies preceded by CT remains to be seen....

"Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours:  a retrospective cohort study"
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60815-0/abstract

Monday, June 11, 2012

News Flash: Diagnostic Tests Take Time

It's a little more insightful than my cynical title indicates, but it is, essentially an article that tries to quantify what we already know - blood tests, MRI, and CT all add to ED length-of-stay.

While the article isn't specifically earthshaking, it interests me in the context of patient flow through the Emergency Department and the utilization of finite ED resources.  Every ED has a waiting room - and, if you're like me, sometimes you look at the board and there are 34 waiting - on a good day.  In that sense, one becomes acutely aware of the value of space in the ED with which to evaluate new patients.  If blood tests and imaging tests are adding over an hour to ED LOS for each of your bed, then it would seem prudent to minimize those tests whenever possible.  It might also, perhaps, even be feasible to consider "standard of care" to be a malleable concept based on a need to ration testing specifically to increase patient flow, balancing the risks of diagnostic uncertainty against the risks of prolonged waiting room times.

Just brought to mind some interesting issues.

"Effect of Testing and Treatment on Emergency Department Length of Stay Using a National Database"
www.ncbi.nlm.nih.gov/pubmed/22594356

Friday, June 8, 2012

Daily Aspirin Harms More Than It Helps

Patients with cardiovascular disease are routinely placed on daily, low-dose aspirin for primary prevention of cardiac events.

Unfortunately, antiplatelet effects promote other types of bleeding, while the cyclooxygenase pathway has a deleterious effect on the gastric mucosal.  This 4.1 million patient propensity matched retrospective database study from Italy demonstrated approximately 2 excess cases of major bleeding events - whether intracranial or gastrointestinal - per 1000 patients treated per year.

Which is approximately the number of major cardiovascular events prevented by the daily aspirin use during the same time period.

Not specifically relevant to Emergency Medicine, but yet another example of how it's naive to think many treatments in medicine - even those (or particularly those!) that have been part of routine practice for eons - are benefiting patients without a significant risk of harms.

"Association of Aspirin Use With Major Bleeding in Patients With and Without Diabetes"
jama.jamanetwork.com/article.aspx?articleid=1172042

Wednesday, June 6, 2012

The Ehrlanger HEARTS3 Score

I hate using the TIMI score to risk-stratify patients in the Emergency Department.  It wasn't derived from a question asked in the Emergency Department, but has been co-opted by hundreds of studies as it has some value as part of our common language with inpatient medicine and cardiology teams.  We're familiar enough with it's shoehorning into our environment that we can use it to assist in some rough decisions about prognosis, but, clearly a better tool must exist.

A couple years back, the HEART score came out of the Netherlands.  In a small derivation and validation cohort, it did a reasonable job of predicting outcomes, using language and variables more relevant to the Emergency Department.  However, these authors from Ehrlanger in Chattanooga recognized one of the limitations of the HEART score was the somewhat arbitrary "expert" weighting of the various elements.  They therefore undertook a study with the goal of using logistic regression and likelihood ratios of the various included elements to expand the score and modify the weighting.

The good news: they improved the AUC of the scoring system from 0.827 and 0.816 for acute MI and 30-day ACS, respectively, to 0.959 and 0.902.  At the reasonable cut-off, the HEARTS3 score gets up close to ~98% sensitivity with ~60% specificity for 30-day ACS.

The bad news: a complex clinical situation requires a complex clinical decision instrument.  No one will be able to hold this in their head like the NEXUS criteria, the TIMI score, or Wells criteria - if we were even bothering to hold all these hundreds of decision instruments in our heads to start.  Luckily, smartphones, the Internet, and decision-support built-in to electronic health records is making progress towards readily available peripheral brains with which to quickly reference risk-stratification instruments such as this.

It still needs external validation, but this is one of the tools seeming to have the greatest potential I've recently seen

"Improving risk stratification in patients with chest pain: the Erlanger HEARTS3 score"
http://www.ncbi.nlm.nih.gov/pubmed/22626816

Monday, June 4, 2012

How Many Emergency Physicians Are On Twitter?

672.

Or, at least, that's how many self-identified in their Twitter profiles as professional physicians in Emergency Medicine at the time this descriptive study was undertaken.  According to the author estimates, this accounts for ~1.6% of the ~20,000 U.S. board-certified Emergency Physicians.  The true number may be higher, owing to profiles that do not identify themselves professionally.

About half were "active" with a tweet within the last 15 days, and the other half were "inactive".  Active accounts followed more users and were followed by more users.  They also have a visualization figure showing the interconnectedness of the active Twitter accounts, and, unsurprisingly, everyone tweets to the same group of twits, and vice versa.

So, it's a small social media extension of the greater online presence of Emergency Physicians.  I'd probably say that the primary flaw with the service, regarding promoting wider interaction between online EPs, is that it is a closed, self-contained system separate from the other online resources visited by EPs.  The value is probably most to those who communicate and interact professionally in an active manner, whereas it doesn't have as much to offer the passive observer.

"Analysis of emergency physicians’ Twitter accounts"
http://www.ncbi.nlm.nih.gov/pubmed/22634832

Saturday, June 2, 2012

Cephalosporins Can Be Used in Penicillin Allergy

Did you know the literature describing the cross-reactivity between cephalosporins and penicillins is 30-40 years old?  It sort of takes the "modern" out of "modern medicine."

At any rate, this is a literature review that aims to update the classical teaching that cross-reactivity between cephalosporins and PCN is ~10%.  They identified 406 articles on the topic and distilled it down to 27 respectable articles for inclusion in summary.  They rate the quality of the articles, and, unfortunately, find only a few good or outstanding articles and a preponderance of adequate evidence.

But, essentially, what they find is the cross-reactivity boils down to the presence of a shared R1 side chain present on first-generation and some second-generation cephalosporins.  Specific first-generation cephalosporins, such as cefadroxil (Duracef), were seen to have up to 28% cross-reactivity in some series, though the typical rate was lower, down to 0.11% with cefazolin (Ancef).  The largest meta-analyses estimated the true cross-reactivity at ~1% rather than 10%, with most of these occurring with first-generation cephalosporins.

In summary - 3rd-generation and greater cephalosporins with disimilar R1 side chains can probably be used in appropriate clinical situations despite a PCN allergy without incidence of allergy greater than in those patients who do not have a documented PCN allergy.

"The use of cephalosporins in penicillin-allergic patients: A literature review."

Thursday, May 31, 2012

Everyone Is On the Cardiac CT Bandwagon


The NEJM is on the wagon with their recent publication.  Annals of EM has been publishing all the ROMICAT trials.  And, not to be outdone, the American College of Cardiology is publishing the CT-STAT trial - a head to head comparison between coronary CT angiogram in the Emergency Department and stress perfusion imaging.

The endpoint of interest, however, is length of stay - and by association total index visit costs - rather than accuracy or safety.  And, in this sense, it was successful.  The primary difference in LOS was the length of time it took to perform the CT or stress test, which was approximately 4 hours quicker in the CT group.  ED costs were also lower, somehow, presumably billing for an observation code while awaiting the stress test and results.

However, what the authors don't include are the total downstream costs and time of additional testing after the Emergency Department visit.  The stress test group had 34 abnormal or non-diagnostic scans, while the CT group had 64.  27 patients in the stress group underwent additional testing vs. 51 in the CT group - mostly stress tests that were subsequently normal - and none of these costs or times are included in their analysis.  I imagine if these extra tests are included in their analysis, the cost difference shrinks or disappears.

It seems to be a trend to advertise more than CT angiography actually delivers.

Several authors are sponsored by Siemens.

"The CT-STAT (Coronary Computed Tomographic Angiography for Systematic Triage of Acute Chest Pain Patients to Treatment) Trial"
www.ncbi.nlm.nih.gov/pubmed/21939822

Tuesday, May 29, 2012

Dabigatran - In Annals of Internal Medicine

My short review article warning the internists of the dangers associated with rushing into overuse of dabigatran was published today in Annals of Internal Medicine.


It was actually originally entitled "Dabigatran – Sinking Into Uncharted Waters," but the editor changed it after the Italian cruise ship disaster.


"Dabigatran — Uncharted Waters and Potential Harms"
http://www.annals.org/content/early/2012/05/23/0003-4819-157-1-201207030-00467

ADAPT 2-Hour Rule Out

I've had a couple questions recently about accelerated rule-out strategies - considering they're in the ACEP Guidelines, but the AHA seems to endorse a viewpoint that any suspicion for cardiac chest pain needs to be taken to its bitter end with a provocative test.  Unfortunately, an all-in strategy doesn't mesh quite as well with reality where the costs are astronomical, and the yield abysmal.

Conveniently, this is another recent study highlighting the use of two sets of biomarkers, two hours apart - using conventional troponin assays.  This is an observational cohort study in Australia and New Zealand investigating the feasibility of their stratification instrument, with the endpoints of "Major Adverse Cardiac Events" within 30 days - an endpoint that, for once, excludes revascularizations.  Specifically, the decision protocol being evaluated includes:
 - Negative troponins at 0 and 2 hours from presentation.
 - No new ischemic changes on ECG.
 - TIMI Score of zero.

Of their 1,976 enrolled patients, 392 met these criteria and were followed for 30 days.  Their single miss was reported as an nSTEMI with two initially negative troponins who subsequently had a positive 12-hour troponin.  Therefore, their sensitivity for 30-day MACE is statistically 98.1% to 99.9%.  This is one of the eight patients in the low-risk cohort who underwent a revascularization procedure in the course of their routine care.

Essentially, using a normal EKG, two negative sets of enzymes, and a risk-stratification instrument - TIMI, Geneva, etc. - the evidence out there lets you have a discussion with the patient regarding their overall risk for a poor outcome.  If you're stuck in a zero-miss environment, then any of these 2-hour protocols will be of no use - they all have a non-negligible miss rate.  But, if you have a grey area to work with, and an otherwise relatively low-risk patient, a quick two-hour troponin helps you catch a few extra fish you otherwise would have missed.

"2-Hour Accelerated Diagnostic Protocol to Assess Patients With Chest Pain Symptoms Using Contemporary Troponins as the Only Biomarker The ADAPT Trial"
www.ncbi.nlm.nih.gov/pubmed/22578923